Spectroscopic investigations of pentobarbital interaction with human serum albumin by Darwish, Saqer M. et al.
This article appeared in a journal published by Elsevier. The attached
copy is furnished to the author for internal non-commercial research
and education use, including for instruction at the authors institution
and sharing with colleagues.
Other uses, including reproduction and distribution, or selling or
licensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of the
article (e.g. in Word or Tex form) to their personal website or
institutional repository. Authors requiring further information
regarding Elsevier’s archiving and manuscript policies are
encouraged to visit:
http://www.elsevier.com/copyright
Author's personal copy
Spectroscopic investigations of pentobarbital interaction with human
serum albumin
Saqer M. Darwish a,*, Sawsan E. Abu sharkh a, Musa M. Abu Teir a, Sami A. Makharza b,
Mahmoud M. Abu-hadid c
a Physics Department, Al-Quds University, P.O. Box 20002, Abu-Dies, Jerusalem, West Bank, Palestine Via, Israel
bNano Technology Lab, Al-Quds University, P.O. Box 20002, Abu-Dies, Jerusalem, West Bank, Palestine Via, Israel
c Immunology Department, Al-Quds University, P.O. Box 20002, Abu-Dies, Jerusalem, West Bank, Palestine Via, Israel
a r t i c l e i n f o
Article history:
Received 8 August 2009
Received in revised form 11 October 2009
Accepted 13 October 2009
Available online 21 October 2009
Keywords:
Pentobarbital
HSA
Binding constant
Protein secondary structure
FT-IR spectroscopy
a b s t r a c t
The interaction between pentobarbital and human serum albumin has been investigated. The basic bind-
ing interaction was studied by UV-absorption and ﬂuorescence spectroscopy. From spectral analysis pen-
tobarbital showed a strong ability to quench the intrinsic ﬂuorescence of HSA through a static quenching
procedure. The binding constant (k) is estimated at 1.812  104 M1 at 293 K. FT-IR spectroscopy with
Fourier self-deconvolution technique was used to determine the protein secondary structure and drug
binding mechanisms. The observed spectral changes of HSA–pentobarbital complex indicate a larger
intensity decrease in the absorption band of a-helix relative to that of b-sheets. This variation in intensity
is related indirectly to the formation of H-bonding in the complex molecules, which accounts for the dif-
ferent intrinsic propensities of a-helix and b-sheets.
 2009 Elsevier B.V. All rights reserved.
1. Introduction
Pentobarbital is in a class of drugs called barbiturates (Fig. 1)
[1]. Barbiturates are substituted pyrimidine derivatives in which
the basic structure common to these drugs is barbituric acid, a sub-
stance which has no central nervous system (CNS) activity, CNS
activity is attained by substituting alkyl, alkenyl, or any groups
on the pyrimidine ring. Pentobarbital is approved for human uses
by the FDA for seizure and preoperative sedation. Pentobarbital
has a variety of effects, including motor impairments, in both hu-
mans and animals [2]. Pentobarbital is capable of having a pro-
found effect on brain function; it is known to depress cerebral
glucose utilization and electrical activity [3].
Human serum albumin (HSA) is the most abundant protein in
blood plasma and is able to bind and thereby transport, various
compounds such as fatty acids, hormones, bilirubin, tryptophan,
steroids, metal ions, therapeutic agents and a large number of
drugs. HSA serves as the major soluble protein constituent of the
circulatory system, it contributes to colloid osmotic blood pressure,
it can bind and carry drugs which are poorly soluble in water [4].
The three-dimensional structure of HSA is determined through
X-ray crystallographic measurements [5]. HSA consists of a single
polypeptide chain of 585 amino acids. Its structure consists of
three homologous domains (labeled as I, II and III), each of which
is divided into two subdomains, A and B, having six and four a-
helices, respectively [6].
The primary pharmacokinetics function of HSA is participating
in absorption, distribution, metabolism and excretion of drugs.
Drugs distribution is mainly controlled by HSA, because most
drugs travel in plasma and reach the target tissues by binding to
HSA [7]. It has been shown that the distribution, free concentration
and the metabolism of various drugs can be signiﬁcantly altered as
a result of their binding to HSA [8].
The binding properties of albumin depend on the three-dimen-
sional structure of the binding sites, which are distributed over the
molecule. Strong binding can decrease the concentrations of free
drugs in plasma, whereas weak binding can lead to a short lifetime
or poor distribution. Its remarkable capacity to bind a variety of
drugs results in its prevailing role in drug pharmacokinetics and
pharmacodynamics [9]. Multiple drug binding sites have been re-
ported for HSA by several researchers [10–16]. The principal re-
gions of ligand binding sites of HSA are located in hydrophobic
cavities in sub domains IIA and IIIA, which are corresponding to
site I and site II, respectively. Site I is dominated by strong hydro-
phobic interaction with most neutral, bulky, heterocyclic com-
pounds, while site II mainly by dipole–dipole, van der Waals,
and/or hydrogen-bonding interactions with many aromatic car-
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boxylic acids. HSA contained a single intrinsic tryptophan residue
(Trp 214) in domain IIA and its ﬂuorescence is sensitive to the li-
gands bounded nearby [17,18]. Therefore, it is often used as a
probe to investigate the binding properties of drugs with HSA.
The modes, speciﬁcities and capacities of ligand binding to
albumin are as diverse as the compounds, which can be bound
[19]. The modes of binding include complex formation with metal
like copper, hydrophobic and electrostatic interaction in high afﬁn-
ity binding and covalent binding to different amino acids. Several
binding sites are distributed over the molecule according to differ-
ent marker molecules [20]. For fatty acids alone, seven binding
sites have been described [16].
Infrared spectroscopy provides measurements of molecular
vibrations due to the speciﬁc absorption of infrared radiation by
chemical bonds. It is known that the form and frequency of the
Amide I band, which is assigned to the C@O stretching vibration
within the peptide bonds is very characteristic for the structure
of the studied protein [21]. From the band secondary structure,
components peaks (a-helix, b-strand) can be derived and the anal-
ysis of this single band allows elucidation of conformational
changes with high sensitivity.
This work will be limited to the mid-range infrared, which cov-
ers the frequency range from 4000 to 400 cm1. This wavelength
region includes bands that arise from three conformational sensi-
tive vibrations within the peptide backbone (Amides I, II and III)
of these vibrations, Amide I is the most widely used and can pro-
vide information on secondary structure composition and struc-
tural stability. One of the advantages of infrared spectroscopy is
that it can be used with proteins that are either in solution or in
thin ﬁlms. In addition, there is a growing body of literature on
the use of infrared to follow reaction kinetics and ligand binding
in proteins, as well as a number of infrared studies on protein
dynamics.
Other spectroscopy techniques are usually used in studying the
interaction of drugs and proteins, ﬂuorescence and UV spectros-
copy are commonly used because of their high sensitivity, rapidity
and ease of implementation. Several reports have been published
studying the interaction of proteins with drugs by ﬂuorescence
technique [22–26].
The binding of pentobarbital to HSA was investigated by means
of UV-absorption spectroscopy, Fluorescence spectroscopy, and FT-
IR spectroscopy. Spectroscopic evidence regarding the drug bind-
ing mode, drug binding constant and the effects of pentobarbital
on the protein secondary structure are provided here.
2. Materials and methods
Pentobarbital in salt form and human serum albumin (fatty acid
free) were purchased from Sigma chemical company and used
without further puriﬁcation.
2.1. Preparation of stock solutions
HSA was dissolved in phosphate buffered saline (80 mg/ml).
The concentration of HSA in the buffer solution was prepared using
its list molecular weight of 66.5 kDa. The solutions of pentobarbital
with the following concentrations 0.015, 0.03, 0.06, 0.12, 0.24, 0.48,
0.96 mM were prepared by dissolving the drug in double distilled
water. In the ﬁnal step drug solution was added to an equal volume
of the protein solution to attain the desired drug concentrations of
0.0075, 0.015, 0.03, 0.06, 0.12, 0.24, 0.48 mM with a ﬁnal protein
concentration of 4% w/v. The solution of pentobarbital and HSA
were incubated for 1 h (at 20 C) before spectroscopic measure-
ments were taken.
2.2. UV-absorption spectra
The absorption spectra were obtained by the use of a NanoDrop
ND-100 spectrophotometer. The absorption spectra were recorded
for free HSA (40 mg/ml) and for its complexes with pentobarbital
solutions with the concentrations of (0.75, 1.5, 3.0, 6.0, 12.0, 24.0,
and 48.0)  105 mol L1. Repeated measurements were done for
all the samples and no signiﬁcant differences were observed.
2.3. Fluorescence
The ﬂuorescence measurements were performed by a Nano-
Drop

ND-3300 Fluorospectrometer at 25 C. The excitation source
comes from one of three solid-state light emitting diodes (LED’s).
The excitation source options include: UV LED with maximum
excitation 365 nm, Blue LED with excitation 470 nm, and white
LED from 500 to 650 nm excitation. A 2048-element CCD array
detector covering 400–750 nm, is connected by an optical ﬁber to
the optical measurement surface. The excitation is done at the
wavelength of 360 nm and the maximum emission wavelength is
at 439 nm.
2.4. FT-IR spectroscopic measurements
The FT-IR measurements were obtained on a Bruker IFS 66/S
spectrophotometer equipped with a liquid nitrogen-cooled MCT
detector and a KBr beam splitter. The spectrometer was continu-
ously purged with dry air during the measurements. Samples are
prepared after 2 h of incubation of HSA with pentobarbital solution
at room temperature, four drops of the serum sample were placed
on a certain area on a silicon window plate and left to dry at room
temperature. The dehydrated ﬁlms on one side of a silicon window
plate of the samples containing different concentrations of pento-
barbital with the same protein content.
The absorption spectra were obtained in the wave number
range of 400–4000 cm1. A spectrum was taken as an average of
60 scans to increase the signal to noise ratio, and the spectral res-
olution was at 4 cm1. The aperture used in this study was 8 mm,
since we found that this aperture gives best signal to noise ratio.
Baseline correction, normalization and peak areas calculations
were performed for all the spectra by OPUS software. The peak
positions were determined using the second derivative of the
spectra.
The infrared spectra of HSA and the pentobarbital–HSA complex
were obtained in the region of 1000–1800 cm1. The FT-IR spec-
trum of free HSA was acquired by subtracting the absorption spec-
trum of the buffer solution from the spectrum of the protein
solution. For the net interaction effect, the difference spectra {(pro-
tein and pentobarbital solution)  (protein solution)} were gener-
ated using the featureless region of the protein solution 1800–
2200 cm1 as an internal standard [27]. The accuracy of this sub-
traction method is tested using several control samples with the
Fig. 1. Chemical structure of pentobarbital.
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same protein or drug concentrations, which resulted into a ﬂat
base line formation. The obtained spectral differences were used
here, to investigate the nature of the drug–HSA interaction.
3. Results and discussion
3.1. UV-absorption spectroscopy
The pentobarbital–HSA binding constants were determined
using UV-absorption spectroscopy as reported for several drug–
protein complexes [28–30]. The absorption spectra for different
concentration of pentobarbital in HSA are shown in Fig 2. Assum-
ing only one type of interaction between pentobarbital and HSA
in aqueous solution, leads to establish Eqs. (1) and (2) as follows:
HSAþ pentobarbital$ pentobarbital : HSA ð1Þ
K ¼ ½pentobarbital : HSA=½pentobarbital½HSA ð2Þ
The absorption data were treated using linear reciprocal plots based
on the following equation [31].
1
A A0 ¼
1
A1  A0 þ
1
K½A1  A0 
1
L
ð3Þ
where A0 corresponds to the initial absorption of protein at 280 nm
in the absence of ligand, A1 is the ﬁnal absorption of the ligated-
protein, and A is the recorded absorption at different pentobarbital
concentrations (L). The double reciprocal plot of 1/(A  A0) vs. 1/L is
linear (Fig. 3) and the binding constant (K) can be estimated from
the ratio of the intercept to the slope to be 1.812  104 M1. The
binding constant value shows a relatively weak pentobarbital–
HSA interaction in comparison to other drug–HSA complexes with
binding constants in the range of 105 and 106 M1 [8]. The reason
for the low stability can be attributed to the presence of mainly
hydrogen-bonding interaction between protein donor atoms and
the pentobarbital polar groups or an indirect drug–protein interac-
tion through water molecules [24].
3.2. Fluorescence spectroscopy
The ﬂuorescence of HSA results from the tryptophan, tyrosine,
and phenylalanine residues. The intrinsic ﬂuorescence of many
proteins is mainly contributed by tryptophan alone, because phen-
ylalanine has very low quantum yield and the ﬂuorescence of tyro-
sine is almost totally quenched if it is ionized or near an amino
group, a carboxyl group, or a tryptophan residue [32]. The ﬂuores-
cence spectra of HSA at various concentrations of pentobarbital
(0.75, 1.5, 3.0, 6.0, 12.0, 24.0, and 48.0)  105 mol L1 are shown
in Fig. 4. The ﬂuorescence intensity of HSA decreased regularly
with the increasing of pentobarbital concentration, while the peak
position shows little or no change at all.
The dynamic quenching process can be described by the Stern–
Volmer equation [22]:
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Fig. 2. UV-absorbance spectra of HSA with different concentrations of pentobar-
bital (a = 0.48 mM, b = 0.24 mM, c = 0.12 mM, d = 0.06 mM, e = 0.03 mM,
f = 0.015 mM, g = 0.0075 mM, h = 0.0 mM, and i = pentobarbital).
Fig. 3. The plot of 1/(A  A0) vs. 1/L for HSA with different concentrations of
pentobarbital.
Fig. 4. Fluorescence emission spectra of HSA in the absence and presence of
pentobarbital in these concentrations (a = 0.0 mM, b = 0.0075 mM, c = 0.015 mM,
d = 0.03 mM, e = 0.06 mM, f = 0.12 mM, g = 0.24 mM, and h = 0.48 mM).
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Fig. 5. The Stern–Volmer plot for pentobarbital–HSA system.
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Fig. 6. The plot of 1/(F0  F) vs. 1/[Q  105].
Fig. 7. The spectra of (A) HSA free (second derivative) and (a, b, c, d, e, f, and g) HSA–pentobarbital with concentrations (0.0, 0.0015, 0.003, 0.006, 0.012, 0.024, and 0.048 mM).
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F0
F
¼ 1þ Kqs0ðLÞ ¼ 1þ KsvðLÞ ð4Þ
where F and F0 are the ﬂuorescence intensities with and without
quencher, Kq is the quenching rate constant of the biomolecule,
Ksv is the Stern–Volmer quenching constant, s0 is the average life-
time of the biomolecule without quencher, and (L) is the concentra-
tion of pentobarbital. As can be seen from Fig. 5, the Stern–Volmer
plot is linear and the slope is equal to Ksv (3.875  107 L mol1).
Fluorescence quenching can be induced by different mechanisms,
which were usually classiﬁed into dynamic quenching and static
quenching. Dynamic quenching arises from Collisional encounters
between the ﬂuorophore and quencher, and static quenching result-
ing from the formation of a ground state complex between the ﬂuo-
rophore and the quencher [33].
The quenching rate constant Kq, can be calculated using the
ﬂuorescence life time of 108 s for HSA [34].
The obtained value of 3.875  1015 L mol1 s1 is much larger
than the maximum dynamic quenching constant for various
quenchers with biopolymer (2  1010 L mol1 s1) [35]. This result
conﬁrms that a static quenching is dominant in the formed com-
plexes [36]. When the static quenching equation is used [33]:
1
F0  F ¼
1
F0KðLÞ þ
1
F0
ð5Þ
where K is the binding constant of pentobarbital with HSA. The va-
lue of K can be determined from the slope and the intercept in Fig. 6.
The value of K is 1.809  104 M1, which agrees well with the value
obtained earlier by UV spectroscopy and supports the effective role
of static quenching. The highly effective quenching constant in this
case has lead to a lower value of binding constant between the drug
and HSA due to an effective hydrogen bonding between pentobarbi-
tal and HSA.
3.3. FT-IR spectroscopy
Infrared spectra of proteins exhibit a number of amide bands,
which represent different vibrations of the peptide moiety. The
amide group of proteins and polypeptides presents characteristic
vibrational modes (amide modes) that are sensitive to the protein
conformation and largely been constrained to group frequency
interpretations [37]. Amide I (1700–1600 cm1 region) is primarily
due to the C@O stretching vibration, Amide II (1600–1480 cm1 re-
gion) to the coupling of the N–H in-plane bending and C–N stretch-
ing modes, and Amide III (1330–1220 cm1 region) to the C–N
stretching coupled to the in-plane N–H bending mode [38–40].
Furthermore, other bands at 900–1300 cm1 were assigned to C–
O bending modes of saccharides (glucose, lactose and glycerol),
the peaks at 1360–1430 cm1 attributed to vibrations of certain
Table 1
Bands assignment in the absorbance spectra of HSA with different pentobarbital concentrations for Amide I–III regions.
Bands HSA
Free
HSA-Pento
0.015 mM
HSA-Pento
0.03 mM
HSA-Pento
0.06 mM
HSA-Pento
0.12 mM
HSA-Pento
0.24 mM
HSA-Pento
0.48 mM
Amide I
(1600–1700)
1614 1615 1614 1613 1613 1614 1612
1626 1627 1626 1626 1626 1626 1627
1637 1637 1636 1637 1637 1636 1639
1656 1657 1656 1656 1656 1654 1657
1683 1680 1681 1682 1681 1682 1680
1693 1691 1692 1693 1692 1694 1692
Amide II
(1480–1600)
1514 1515 1515 1515 1515 1515 1515
1532 1532 1532 1531 1531 1531 1532
1544 1548 1546 1546 1546 1544 1548
1564 1568 1570 1571 1570 1571 1568
1579 1579 1582 1581 1581 1585 1584
1594 1595 1595 1595 1595 1594 1596
Amide III
(1220–1330)
1226 1226 1226 1226 1226 1226 1226
1242 1243 1243 1243 1243 1242 1243
1269 1267 1269 1268 1268 1268 1267
1293 1292 1293 1294 1293 1293 1294
1313 1312 1313 1314 1313 1313 1312
Fig. 8. FT-IR spectra (top two curves) and difference spectra of HSA and its
complexes with different pentobarbital concentrations in the region of 1800–
1500 cm1.
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amino acids chains and 1430–1480 cm1 is attributed to fatty
acids, phospholipids and triglycerides [41,42].
The second derivative of the FT-IR spectrum for HAS free, and
the spectra for HSA with different concentrations of pentobarbital
are shown in Fig. 7, where the spectra are dominated by the absor-
bance bands of Amides I and II at 1655 and 1545 cm1, respec-
tively. The peak positions of Amide I bands in HSA infrared
spectrum shifted as listed in Table 1: 1615–1612 cm1, 1626–
1627 cm1, 1683–1680 cm1, 1656–1657 cm1 and 1693–
1692 cm1 after interaction with pentobarbital. In addition a peak
at 1636 cm1 has disappeared after the interaction with pentobar-
bital. The changes of these peak positions and peak shapes demon-
strated the secondary structures of the HSA had been changed by
the interaction of pentobarbital with HSA. In Amide II region some
of the peak positions have shifted in the following order: 1544–
1548 cm1, 1564–1568 cm1 and 1594–1596 cm1. In the Amide
III region little or no change of the peak positions has been ob-
served. The minor changes in peak positions can be attributed to
the effect of the newly imposed H-bonding between the drug mol-
ecules and the protein. It is suggested that, the shift to a higher fre-
quency for the major peak in Amide1 region (1656–1657) came as
a result of stabilization by hydrogen bonding by having the C–N
bond assuming partial double bond character due to a ﬂow of elec-
trons from the C@O to the C–N bond [43].
The component bands of Amide I were attributed according to
the well-established assignment criterion [44–45]. The bands
range 1610–1640 cm1 are generally assigned to b-sheet, 1640–
1650 cm1 to random coil, 1650–1658 cm1 to a-helix and
1660–1700 cm1 to b-turn structure. As for Amide II, the absorp-
tion band consists of four components and assigned in the follow-
ing order: 1488–1500 cm1 to b-sheets, 1504–1525 cm1 to
random coil, 1527–1560 cm1 to a-helix and 1564–1585 cm1 to
turn structure [46]. The component bands of Amide III have been
assigned as follows: a-helix 1330–1290 cm1, b-turn 1290–
1270 cm1, random coil 1270–1250 cm1 and b-sheet 1250–
1220 cm1[45].
Most investigations have concentrated on Amide I band assum-
ing higher sensitivity to the change of protein secondary structure
[47]. However, it has been reported that the Amide II band has high
information content and could be used alone for secondary struc-
ture prediction in place of Amide I [48–49]. Others have reported
that Amide III is not directly affected by the strong water band
and therefore it has been used for structure determinations [50].
The difference spectra [(protein + pentobarbital)  (protein)]
were obtained to investigate the intensity variations and the re-
sults are shown in Fig. 8. Two strong negative features at 1654
and 1543 cm1 were observed at low pentobarbital concentration
(0.03 mM). These two negative features became even stronger at
lower concentrations with a little shift in their positions. The ob-
served negative features are attributed to the decrease of intensi-
ties at Amide I band at1654 and Amide II band at 1543 as a
result of drug interaction (H-bonding) with protein C@O and C–N
groups [24].
In this work, a quantitative analysis of the protein secondary
structure for the free HSA and pentobarbital–HSA complex in
dehydrated ﬁlms is determined from the shape of Amide I, II and
III bands. Infrared Fourier self-deconvolution with second deriva-
tive resolution and curve ﬁtting procedures [51–52], were applied
to increase spectral resolution and therefore to estimate the num-
ber, position and area of each component bands. The procedure
was in general carried out considering only components detected
by second derivatives and the half widths at half height (HWHH)
for the component peaks are kept around 5 cm1. Based on the
above assignments, the percentages of each secondary structure
of HSA were calculated from the integrated areas of the component
bands in Amides I, II and III, respectively. Table 2 shows the content
of each secondary structure of HSA before and after the interaction
with pentobarbital at different concentrations.
Table 2
Secondary structure determination for Amide I–III regions in HSA and its pentobarbital complexes.
Bands HSA
Free
HSA-Pento
0.015 mM
HSA-Pento
0.03 mM
HSA-Pento
0.06 mM
HSA-Pento
0.12 mM
HSA-Pento
0.24 mM
HSA-Pento
0.48 mM
Amide I
b-Sheets (cm1)
(1610–1640)
(1680–1700)
16 18 16 18 17 17 19
Random (cm1)
(1640–1650)
15 14 16 16 16 18 13
a-Helix (cm1)
(1650–1660)
55 51 51 49 49 49 48
Turn (cm1)
(1660–1680)
14 17 17 17 16 16 20
Amide II
b-Sheets (cm1)
(1488–1500)
(1587–1598)
18 18 17 17 18 17 19
Random (cm1)
(1504–1525)
14 11 12 14 13 14 10
a-Helix (cm1)
(1527–1560)
50 50 51 48 50 50 47
Turn (cm1)
(1564–1583)
18 21 20 21 19 19 24
Amide III
b-Sheets (cm1)
(1220–1254)
17 17 18 19 20 20 21
Random (cm1)
(1258–1280)
15 16 15 16 15 16 16
Turn (cm1)
(1283–1298)
18 18 18 17 17 17 17
a-Helix (cm1)
(1298–1325)
50 49 49 48 48 47 46
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Fig. 9 reveals second derivative resolution enhancement and
curve-ﬁtted Amide I region and secondary structure determina-
tions of the free human serum albumin (A and B) and its pentobar-
bital complexes (C and D) in dehydrated ﬁlms. It is generally
accepted that infrared spectra of proteins in ﬁlms and in solution
may display distinct differences, but these differences are due to
the presence or absence of the water or buffer molecules that im-
print their mark on the spectra. It has been shown that the struc-
tural information content is of the same quality in ﬁlms and in
solution with an (error of <1%) for both systems [53].
The percentage values for the components of Amide I of free
HSA are consistent with the results of other recent spectroscopic
studies [54–55]. The results of Amide II and Amide III showed sim-
ilar trends in their percentage values to that of Amide I. The de-
crease of a-helix percentage with the increase of pentobarbital
concentrations is evident in the calculations and this trend is con-
sistent in the three Amide regions. However, for the b-sheet the
relative percentage has increased with increasing pentobarbital
concentrations. The reduction of a-helix intensity percentage in fa-
vour of the increase of b-sheets and turn structure are believed to
be due to the unfolding of the protein in the presence of pentobar-
bital as a result of the formation of H-bonding between HSA and
the drug. The steric blocking effect can contribute an enthalpic sta-
bilization to intraprotein hydrogen bonds and disfavors peptide to
catalyst complexation in hydrogen exchange reactions and peptide
to peptide H-bonding in the helical main chain conformation but
not in b-strands [56]. The newly formed H-bonding result in the
C–N bond assuming partial double bond character due to a ﬂow
of electrons from the C@O to the C–N bond which decreases the
intensity of the original vibrations [43]. It seems that the H-bond-
ing effects more of the original bonding in a-helix than in b-sheets
depending on the accessibility of the solvent and on propensities of
a-helix and b-sheets of the protein [57]. The hydrogen bonds in a-
helix are formed inside the helix and parallel to the helix axis,
while for b-sheet the hydrogen bonds take position in the planes
of b-sheets as the preferred orientations especially in the anti-par-
allel sheets. The restrictions on the formation of hydrogen bonds in
b-sheet relative to the case in a-helix explain the larger effect on
reducing the intensity percentage of a-helix to that of b-sheet.
Similar conformational transitions from an a-helix to b-sheet
structure were observed for the protein unfolding upon proton-
ation and heat denaturation [58–59].
In summary, the binding of pentobarbital to HSA has been
investigated by UV-absorption spectroscopy, ﬂuorescence spec-
troscopy and by FT-IR spectroscopy. From the UV and Fluorescence
Investigations, we determined values for the binding constant and
the quenching constant. The results indicate that the intrinsic ﬂuo-
rescence of HSA was quenched by pentobarbital through static
quenching mechanism. Analysis of the FT-IR spectra reveals that
HSA–pentobarbital interaction induces intensity reduction in the
absorption bands of a-helix and b-sheets components with differ-
ent proportionality due to the different accessibility of H-bond for-
mation in these components.
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